Xtant Medical Holdings, Inc.
XTNT · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -1.92 | -0.12 | 0.13 |
| FCF Yield | -27.04% | -8.15% | -11.44% | -3.50% |
| EV / EBITDA | -11.19 | 30.03 | -10.85 | -18.49 |
| Quality | ||||
| ROIC | -15.47% | 8.60% | -13.29% | -9.73% |
| Gross Margin | 58.17% | 60.75% | 55.44% | 58.79% |
| Cash Conversion Ratio | 0.72 | -14.42 | 0.63 | -0.09 |
| Growth | ||||
| Revenue 3-Year CAGR | 26.47% | 18.22% | 2.81% | -5.11% |
| Free Cash Flow Growth | -45.92% | -54.41% | -323.93% | 26.36% |
| Safety | ||||
| Net Debt / EBITDA | -3.67 | 3.52 | 0.59 | 0.56 |
| Interest Coverage | -2.90 | -3.46 | -3.99 | -3.87 |
| Efficiency | ||||
| Inventory Turnover | 1.27 | 0.97 | 1.49 | 1.27 |
| Cash Conversion Cycle | 292.87 | 386.71 | 263.26 | 292.96 |